Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of ...

In total, 28 patients received farletuzumab and 46 patients received farletuzumab in combination with standard platinum and taxane chemotherapy. The researchers reported preliminary data from 41 ...

Adding adjuvant taxane therapy to an anthracycline-containing chemotherapy regimen has been shown to reduce the risks of disease recurrence and death in women with operable breast cancer.